The Cardiovascular Clinical Research Center was established in 2003 under the direction of Dr. Judith S. Hochman, the Snyder Family Professor of Cardiology. The Cardiovascular Clinical Research Center is designed to facilitate all aspects of patient-based clinical research and education. This includes coordination of multicenter trials; support of the infrastructure for clinical research trials; as well as education of faculty, fellows and more junior trainees in clinical research methodology. Since its inception, the Cardiovascular Clinical Research Center has coordinated dozens of investigator initiated and multicenter cardiovascular clinical research trials at NYU-Langone Medical Center and throughout the world.
The Cardiovascular Clinical Research Center Associate Director is Dr. Harmony Reynolds and Dr. Stuart Katz serves as the Director of Clinical Research Training. The Cardiovascular Clinical Research Center is also comprised of numerous cardiology investigators, grants manager, project managers, research coordinators, and project support staff.
The Cardiovascular Clinical Research Center at NYU School of Medicine encompasses a Clinical Coordinating Center which is involved in the conduct of an international randomized trial, the Occluded Artery Trial, funded by The National Heart, Lung and Blood Institute. The Cardiovascular Clinical Research Center has also led two international multi-center, randomized divided trials of pharmacologic agent in cardiogenic shock. The Cardiovascular Clinical Research Center is involved in the conduct of randomized clinical trials and registries of patients with coronary artery disease, hypertension, heart failure, unstable angina and acute myocardial infarction as well as percutaneous treatment of valvular heart disease. In addition, this Center is the Clinical Coordinating Center for large international multicenter trials, such as the Occluded Artery Trial (OAT), funded by The National Heart, Lung and Blood Institute under my direction as Study Chair. Recent and ongoing studies include NHLBI funded trials such as FREEDOM, VIRGO, BARI 2D, Reveal, TACT, TOPCAT industry trials such as TRILOGY, PROTECT, Tecos, STABILITY, EXCEL, EXSCEL, and EVEREST II, among others.
The Occluded Artery Trial (OAT), a large clinical trial funded by the National Heart Lung and Blood Institute (NHLBI). OAT involves 2201 patients and 217 centers worldwide and is a landmark study. This study specifically looked at whether opening an occluded infarct related artery (IRA) with percutaneous coronary intervention 3 to 28 days after an acute myocardial infarction in high-risk asymptomatic patients would reduce the rate death, MI or hospitalization for class IV heart failure.